Exploring the FDA Approval of Zolbetuximab for Gastric Cancer

This chapter discusses the FDA's approval of Zolbetuximab, a monoclonal antibody for HER2 negative stomach and gastroesophageal junction adenocarcinoma. It covers dosing, mechanism of action, clinical trial efficacy, potential adverse effects, and administration considerations.